Champions Oncology (CSBR) Cash & Current Investments (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Cash & Current Investments of $7.1 million in Q1 2026, down 16.63% quarter-over-quarter from $8.5 million in Q4 2025, and up 121.74% on a YoY basis from $3.2 million in Q1 2025.
Champions Oncology (CSBR) Cash & Current Investments (2010 - 2026) Analysis & Trends
Champions Oncology's Cash & Current Investments history runs 17 years deep, the most recent figure standing at $7.1 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 121.74% year-over-year to $7.1 million; the TTM figure through Jan 2026 stood at $7.1 million (up 121.74% YoY), while the FY2025 annual figure was $9.8 million, up 273.76% from the prior year.
- Cash & Current Investments was $7.1 million for Q1 2026 at Champions Oncology, down from $8.5 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $10.8 million in Q4 2022 to a low of $2.6 million in Q2 2024.
- Historically, Cash & Current Investments has averaged $6.3 million across 5 years, with a median of $5.5 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Cash & Current Investments tumbled 50.05% in 2024, then surged 273.76% in 2025.
- A 5-year view of Cash & Current Investments shows it stood at $10.8 million in 2022, then tumbled by 49.08% to $5.5 million in 2023, then sank by 50.05% to $2.8 million in 2024, then jumped by 209.22% to $8.5 million in 2025, then slipped by 16.63% to $7.1 million in 2026.
- The last three Cash & Current Investments figures came in at $7.1 million (Q1 2026), $8.5 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | 7.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 7.10 Mn |
| Oct 31, 2025 | 8.52 Mn |
| Jul 31, 2025 | 10.30 Mn |
| Apr 30, 2025 | 9.79 Mn |
| Jan 31, 2025 | 3.20 Mn |
| Oct 31, 2024 | 2.75 Mn |
| Jul 31, 2024 | 2.89 Mn |
| Apr 30, 2024 | 2.62 Mn |
| Jan 31, 2024 | 4.50 Mn |
| Oct 31, 2023 | 5.51 Mn |
| Jul 31, 2023 | 4.90 Mn |
| Oct 31, 2022 | 10.83 Mn |
| Jan 31, 2022 | 8.70 Mn |
| Jul 31, 2021 | 4.00 Mn |
| Jul 31, 2020 | 6.94 Mn |
| Apr 30, 2020 | 8.34 Mn |
| Jan 31, 2020 | 3.28 Mn |
| Oct 31, 2019 | 2.78 Mn |
| Jul 31, 2019 | 2.20 Mn |
| Apr 30, 2019 | 3.24 Mn |